Headlines about Sarepta Therapeutics (NASDAQ:SRPT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8343429956986 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Shares of Sarepta Therapeutics (SRPT) traded up $0.84 during trading hours on Wednesday, hitting $55.05. 1,287,489 shares of the stock traded hands, compared to its average volume of 2,258,089. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.66. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same period in the prior year, the business earned ($0.95) earnings per share. sell-side analysts anticipate that Sarepta Therapeutics will post -3.11 EPS for the current year.

Several equities research analysts have weighed in on the company. HC Wainwright assumed coverage on Sarepta Therapeutics in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 target price for the company. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Robert W. Baird restated a “buy” rating and set a $101.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. Finally, Oppenheimer restated a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $64.14.

In related news, CEO Douglas S. Ingram acquired 38,138 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the acquisition, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the sale, the senior vice president now owns 37,045 shares of the company’s stock, valued at $2,037,475. The disclosure for this sale can be found here. Insiders sold 28,167 shares of company stock valued at $1,497,619 over the last 90 days. 9.60% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics (SRPT) Receives News Sentiment Rating of 0.17” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-srpt-receives-news-sentiment-rating-of-0-17/1775189.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.